Citations

Clear

6274 citation(s) found for "To, Andrew".

Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).
Liu, Minetta C. , Frith, Ashley , Lyss, Alan P., Weckstein, Douglas, Moreno‐Aspitia, Alvaro , Le‐Lindqwister, Nguyet, Wender, Donald B., Lewis, DeQuincy Andrew, Cole, John T., Jaslowski, Anthony J., Rowland, Kendrith M. , Openshaw, Thomas H. , Friday, Bret Edward Buckley, Asmus, Erik, Rogak, Lauren J. , Basch, Ethan , Hillman, David W. , Isaacs, Claudine , Fleming, Gini F. , Basch, Ethan , Dueck, Amylou C.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 1016-1016

10.1200/jco.2020.38.15_suppl.1016 Get It

1016 Background: The ph III EMBRACE trial of E vs physician’s choice of tx led to FDA approval of E as ≥3rd-line tx for MBC pts with prior exposure to anthracyclines/taxanes. The ph III BOLD 301 trial of E vs capecitabine in advanced BC treated with anthracyclines/taxanes showed a nonsignificant trend to improved median OS for all pts; pre-planned analysis by HER2 status revealed a nominally significant benefit for HER2- pts. Methods: RU011201I is an investigator initiated ph III trial with 1:1 randomization to E (1.4 mg/m2 D1,8 q21days) vs P (90 mg/m2 D1,8,15 q28days) within strata defined by (neo)adjuvant taxanes (yes/no), HR status (+/-), and line of tx (1st/2nd). Pts had measurable or non-measurable disease by RECIST v1.1; new or progressive mets; peripheral neuropathy (PN) gr<2; ≤1 prior chemotx regimens for advanced or MBC. Asymptomatic brain mets with stable MRIs for >3 mos were allowed. (Neo)adjuvant taxanes were allowed if >12 mos between tx completion and disease recurrence. Radiographic studies occur q12wks. Survival data are collected q12wks after the Off-Tx Visit. Pts reported side effects weekly; post-baseline symptomatic AE rates worse than baseline were compared between arms using Fisher’s exact tests. We report clinical outcomes and the primary objective related to PRO-CTCAE use. Results: 201 pts enrolled 3/2014 - 5/2018 with 33.8 mos median f/u; 3 are on tx as of 2/20/20 (1E, 2P). Pt characteristics were the same between E vs P: median age 62 yrs (range 27-85); 42% prior taxane; 78% ER+; 70% starting 1st line tx. Baseline lesion distribution was similar except for lung mets (37E, 53P). No difference was seen between E vs P in PFS (5.7 vs 5.9 mos; P=0.72), OS (18.1 vs 16.4 mos; P=0.75), TTF (5.3 vs 4.9 mos; P=0.82), DOR (10.8 vs 12.3 mos; P=0.84), or number of metastatic events (55 vs 54). 37E and 36P pts required ≥1 dose reduction. Hematologic toxicities ≥ gr 3 were higher with E (40 vs 22%). PN events were similar: 56 vs 58 total, 4 vs 7 motor, 52 vs 51 sensory. Median duration of PN and median time to 1st PN event were 74 vs 140 and 56 vs 41 days. Worsened numbness/tingling severity and other pt-reported AE rates were similar, but worsened numbness/tingling interference (63% vs 78%, P=0.04) and vomiting frequency (35% vs 57%, P=0.005) were lower with E. Conclusions: Clinical outcomes were equivalent with E vs P as 1st/2nd line tx for HER2- advanced BC. The nature and severity of PN were similar between arms, but time of onset, duration, and interference with daily living favor E. E may be a suitable treatment option in this setting. Clinical trial information: NCT02037529 .
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
Bustoros, Mark , Sklavenitis‐Pistofidis, Romanos , Park, Jihye , Zhitomirsky, Benny , Salem, Karma Z. , Chavda, Selina J , Boehner, Cody J. , Elagina, Liudmila, Neuse, Carl Jannes , Cha, Justin , Rahmat, Mahshid , Kumar, Shaji , Kastritis, Efstathis, Laubach, Jacob P. , Casneuf, Tineke, Richardson, Paul G. , Munshi, Nikhil C. , Trippa, Lorenzo , Bergsagel, P. Leif , Manier, Salomon , Ghobrial, Irene M. , Bergsagel, P. Leif , Ghobrial, Irene M , Sklavenitis-Pistofidis, Romanos , Redd, Robert , Dunford, Andrew , Tai, Yu‐Tzu , Anand, Shankara K. , Mouhieddine, Tarek H. , Taylor-Weiner, Amaro N , Van Allen, Eliezer M , Leshchiner, Ignaty , Morgan, Elizabeth A. , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Aguet, François , Stewart, Chip , Dimopoulos, Meletios Α. , Yong, Kwee , Getz, Gad

Mayo Clinic

Journal of Clinical Oncology | May 22, 2020 | Volume: 38 | Issue: 21 | Pages: 2380-2389

10.1200/jco.20.00437 | PMID 32442065 Get It

PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. METHODS We used next-generation sequencing to study 214 patients with SMM. We performed whole-exome sequencing on 166 tumors, including 5 with serial samples, and deep targeted sequencing on 48 tumors. RESULTS We observed that most of the genetic alterations necessary for progression have already been acquired by the diagnosis of SMM. Particularly, we found that alterations of the mitogen-activated protein kinase pathway ( KRAS and NRAS single nucleotide variants [SNVs]), the DNA repair pathway (deletion 17p, TP53, and ATM SNVs), and MYC (translocations or copy number variations) were all independent risk factors of progression after accounting for clinical risk staging. We validated these findings in an external SMM cohort by showing that patients who have any of these three features have a higher risk of progressing to MM. Moreover, APOBEC associated mutations were enriched in patients who progressed and were associated with a shorter time to progression in our cohort. CONCLUSION SMM is a genetically mature entity whereby most driver genetic alterations have already occurred, which suggests the existence of a right-skewed model of genetic evolution from monoclonal gammopathy of undetermined significance to MM. We identified and externally validated genomic predictors of progression that could distinguish patients at high risk of progression to MM and, thus, improve on the precision of current clinical models.
Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome
Lahrouchi, Najim , Crotti, Lia , Mizusawa, Yuka , Postema, Pieter G. , Beekman, Leander , Walsh, Roddy , Hasegawa, Kanae , Barc, Julien , Ernsting, Marko, Turkowski, Kari L. , Mazzanti, Andrea , Beckmann, Britt M., Diamant, Ulla‐Britt , Kucho, Yu, Robyns, Tomas , Winbo, Annika , Jabbari, Reza , Lubitz, Steven A., Steinfurt, Johannes , Rudic, Boris , Shoemaker, Moore B., Weeke, Peter , Davies, Brianna , Andorin, Antoine , Hofman, Nynke , Pedrazzini, Matteo , Tester, David J. , Bos, J. Martijn , Platonov, Pyotr G. , Stallmeyer, Birgit, Zumhagen, Sven, Nannenberg, Eline A., Veldink, Jan H., Berg, Leonard H. van den, Al‐Chalabi, Ammar , Shaw, Christopher E. , Shaw, Pamela J. , Morrison, Karen , Müller‐Nurasyid, Martina , Cusi, Daniele , Lathrop, Mark , Munter, Markus, Aung, Tin , Ozaki, Mineo , Lichtner, Peter , Tintelen, J. Peter van , Hoedemaekers, Yvonne M., Napolitano, Carlo , Gourraud, Jean‐Baptiste , Makiyama, Takeru , Ohno, Seiko , Itoh, Hideki , Roden, Dan M. , Saenen, Johan , Borggrefe, Martin, Odening, Katja E. , Ellinor, Patrick T., Tfelt‐Hansen, Jacob , Skinner, Jonathan R. , Berg, Maarten P. van den , Makita, Naomasa , Breckpot, Jeroen , Yoshinaga, Masao , Behr, Elijah R. , Rydberg, Annika , Aiba, Takeshi , Priori, Silvia G. , Newton‐Cheh, Christopher , Schulze‐Bahr, Eric , Horie, Minoru , Wilde, Arthur A.M. , Tanck, Michael W.T. , Bezzina, Connie R. , Lubitz, Steven A. , Crotti, Lia , Makita, Naomasa , Horie, Minoru , Behr, Elijah Raphael , van Tintelen, J Peter , Odening, Katja E , Bos, Johan M , Tanck, Michael , Barc, Julien , Tfelt-Hansen, Jacob , Skinner, Jonathan R , van den Berg, Maarten P , Robyns, Tomas , Lubitz, Steven A , Al-Chalabi, Ammar , Bezzina, Connie R , Gourraud, Jean-Baptiste , Mazzanti, Andrea , Postema, Pieter G , Priori, Silvia , Walsh, Roddy , Tadros, Rafik , Beckmann, Britt-Maria, Shimamoto, Keiko , Wijeyeratne, Yanushi D. , Ishikawa, Taisuke , Arbelo, Elena , Christiansen, Michael , Loeys, Bart , Pfeiffer, Ryan D. , Dagradi, Federica , Sarquella-Brugada, Georgia , Campuzano, Óscar , Berg, Leonard H. van den , Andersen, Peter Munch , Barlassina, Cristina , Galán, Pilar , Werge, Thomas Mears , Ribasés, Marta , Khor, Chiea Chuen , Meitinger, Thomas , Denjoy, Isabelle , Leenhardt, Antoine , Shimizu, Wataru , Schott, Jean‐Jacques , Ohno, Seiko , Krahn, Andrew D. , Antzelevitch, Charles , Roden, Dan M. , Ellinor, Patrick T. , Olesen, Morten S. , Brugada, Josép , Brugada, Ramón , Aiba, Takeshi , Kääb, Stefan , Guicheney, Pascale , Tan, Hanno L. , Ackerman, Michael , Schwartz, Peter J. , Probst, Vincent

Mayo Clinic

Circulation | May 20, 2020 | Volume: 142 | Issue: 4 | Pages: 324-338

10.1161/circulationaha.120.045956 | PMID 32429735 Get It

Background: Long QT syndrome (LQTS) is a rare genetic disorder and a major preventable cause of sudden cardiac death in the young. A causal rare genetic variant with large effect size is identified in up to 80% of probands (genotype positive) and cascade family screening shows incomplete penetrance of genetic variants. Furthermore, a proportion of cases meeting diagnostic criteria for LQTS remain genetically elusive despite genetic testing of established genes (genotype negative). These observations raise the possibility that common genetic variants with small effect size contribute to the clinical picture of LQTS. This study aimed to characterize and quantify the contribution of common genetic variation to LQTS disease susceptibility. Methods: We conducted genome-wide association studies followed by transethnic meta-analysis in 1656 unrelated patients with LQTS of European or Japanese ancestry and 9890 controls to identify susceptibility single nucleotide polymorphisms. We estimated the common variant heritability of LQTS and tested the genetic correlation between LQTS susceptibility and other cardiac traits. Furthermore, we tested the aggregate effect of the 68 single nucleotide polymorphisms previously associated with the QT-interval in the general population using a polygenic risk score. Results: Genome-wide association analysis identified 3 loci associated with LQTS at genome-wide statistical significance ( P <5×10 −8 ) near NOS1AP , KCNQ1 , and KLF12 , and 1 missense variant in KCNE1 (p.Asp85Asn) at the suggestive threshold ( P <10 −6 ). Heritability analyses showed that ≈15% of variance in overall LQTS susceptibility was attributable to common genetic variation ( h2SNP 0.148; standard error 0.019). LQTS susceptibility showed a strong genome-wide genetic correlation with the QT-interval in the general population (r g =0.40; P =3.2×10 −3 ). The polygenic risk score comprising common variants previously associated with the QT-interval in the general population was greater in LQTS cases compared with controls ( P <10−13), and it is notable that, among patients with LQTS, this polygenic risk score was greater in patients who were genotype negative compared with those who were genotype positive ( P <0.005). Conclusions: This work establishes an important role for common genetic variation in susceptibility to LQTS. We demonstrate overlap between genetic control of the QT-interval in the general population and genetic factors contributing to LQTS susceptibility. Using polygenic risk score analyses aggregating common genetic variants that modulate the QT-interval in the general population, we provide evidence for a polygenic architecture in genotype negative LQTS.
Hypoglossal Nerve Stimulator Implantable Pulse Generator Exchange for Battery Depletion
Goates, Andrew J., Louis, Erik K. St. , Olson, Michael D. , St Louis, Erik K, St Louis, E K , Goates, Andrew J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | May 19, 2020 | Volume: 163 | Issue: 2 | Pages: 389-390

10.1177/0194599820925767 | PMID 32427546 Get It

Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events
Kunchok, Amy , Aksamit, Allen J. , Davis, John M. , Kantarci, Orhun H. , Pittock, Sean J. , Weinshenker, Brian G. , Pittock, S J , Weinshenker, Brian G , Pittock, Sean J , Davis, John M , Keegan, B. Mark , McKeon, Andrew

Mayo Clinic

JAMA Neurology | May 18, 2020 | Volume: 77 | Issue: 8 | Pages: 937

10.1001/jamaneurol.2020.1162 | PMID 32421186 Get It

Colonic Angiosarcoma Arising in Association with Amyloid Deposits
Said, Samar M. , Graham, Rondell P. , Wu, Tsung‐Teh, Yasir, Saba , Zhang, Lizhi , Folpe, Andrew L. , Said, Samar , Graham, Rondell P

Mayo Clinic

Case Reports in Gastrointestinal Medicine | May 16, 2020 | Volume: 2020 | Issue: No issue available | Pages: 1-6

10.1155/2020/3780763 | PMID 32509358 Get It

Angiosarcoma of the colon is rare, as is colonic amyloidosis. To our knowledge, there have been no reported cases of angiosarcoma arising in association with amyloid deposition. Herein, we described a case of 77-year-old man who presented with hematochezia, and a sigmoid mass was found on colonoscopy. Histologic examination of the resected specimen showed extensive nodular deposition of AL-lambda amyloid material in the colonic wall, as well as high-grade angiosarcoma which was closely intermingled with the amyloid deposits. While the occurrence of both colonic amyloidosis and angiosarcoma in this patient may represent pure coincidence, given the intimate association of the angiosarcoma and the amyloid deposition and the rarity of both of these lesions, we hypothesize that angiosarcoma could be secondary to amyloid deposition.
Discordant Values in Lower Extremity Physiologic Studies Predict Increased Cardiovascular Risk
Firth, Christine , Abdelmalek, Mina, Girardo, Marlene , Atwal, Danish, Pollak, Amy W., Liedl, David , Wennberg, Paul W. , Shamoun, Fadi , Tseng, Andrew S. , Pollak, Amy, Wennberg, Paul, Shamoun, Fadi Elias, Cooper, Leslie T. , McBane, Robert D.

Mayo Clinic

Journal of the American Heart Association | May 16, 2020 | Volume: 9 | Issue: 11 | Pages: No page available

10.1161/jaha.119.015398 | PMID 32419570 Get It

Background Ankle‐brachial indexes ( ABI ) are a noninvasive diagnostic tool for peripheral arterial disease and a marker of increased cardiovascular risk. ABI is calculated using the highest systolic blood pressure of the 4 ankle arteries (bilateral dorsalis pedis and posterior tibial). Accordingly, patients may be assigned a normal ABI when the result would be abnormal if calculated using one of the other blood pressure readings. Cardiovascular outcomes for patients with discordant ABI s are undescribed. Methods and Results We performed a retrospective study of patients who underwent ABI measurement for any indication between January 1996 and June 2018. Those with normal ABI s (1.00–1.39) were included. We compared patients with all 4 normal ABI s (calculated using all 4 ankle arteries; n=15 577, median age 64.0 years, 54.4% men) to those with discordant ABI s (at least 1 abnormal ABI ≤0.99; n=2095, median age 66.0 years, 47.8% men). The outcomes assessed were ischemic stroke, myocardial infarction, and all‐cause mortality. Compared with patients with concordant normal ABI s, patients with discordant ABI s were older; women; smoked; and had chronic kidney disease, coronary artery disease, diabetes mellitus, chronic obstructive pulmonary disease, hypertension, or prior stroke. Patients with discordant ABI s had a greater risk of myocardial infarction (hazard ratio [HR], 1.31; 95% CI, 1.10–1.56), ischemic stroke ( HR, 1.53; 95% CI, 1.37–1.72), and all‐cause mortality ( HR, 1.27; 95% CI, 1.16–1.39), including after adjustment for baseline comorbidities. Conclusions Discordant ABI results were associated with an increased risk of myocardial infarction, stroke, and all‐cause mortality in the studied population. Clinicians should examine ABI calculations using all 4 ankle arteries to better characterize a patient's cardiovascular risk.
Abstract 241: Health-related Quality of Life in Patients With Recurrent Pericarditis: Results From a Phase 2 Study of Rilonacept
Lin, David , Klein, Allan, Cella, David , Beutler, Anna , Fang, Fang , Magestro, Matt , LeWinter, Martin M. , Abbate, Antonio , Ertel, Andrew, Litcher‐Kelly, Leighann , Klooster, Brittany , Paolini, John F. , Klein, Allan L. , Cremer, Paul , Luis, Sushil Allen

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 14, 2020 | Volume: 13 | Issue: Suppl_1 | Pages: No page available

10.1161/hcq.13.suppl_1.241 Get It

Background: Recurrent pericarditis (RP) episodes and conventional treatments result in morbidity, but the impact on patient health-related quality of life (HRQoL) has not been quantified. The Phase 2 trial NCT03980522 of rilonacept (IL-1α/IL-1β inhibitor) evaluated HRQoL. Methods: Patients with active RP who were symptomatic at Baseline (A-RP, n=16) and RP patients who were not currently experiencing a recurrence but were corticosteroid-dependent at Baseline (CSD-RP, n=9) were enrolled. All received rilonacept weekly for 6 weeks to end of base treatment period (TP) plus an optional 18-week extension treatment period (EP). Corticosteroid tapering occurred in the EP. Physical and mental HRQoL (PROMIS Global Health v1.2 Physical and Mental Component Scores [PCS/MCS]) were assessed at baseline and follow-up. Results: Figure 1 presents the PROMIS PCS/MCS and pain scale scores (both patient-reported) as well as C-reactive protein levels over time. Mean PCS/MCS scores at baseline were 39.9/44.5 and 43.3/46.5 for A-RP and CSD-RP groups respectively (versus the norm mean of 50). In A-RP, PCS/MCS scores improved by 11.4/5.6 points by end of base TP, and this improvement was sustained throughout the EP (increase of 11.4/6.0 points from baseline at end of EP). In CSD-RP, PCS/MCS scores increased by 1.8/1.4 points by end of TP and improved by 3.5/4.2 points at end of study, after tapering or discontinuation of corticosteroid without disease recurrence. Conclusion: Impaired baseline HRQoL suggests negative impact of RP. For A-RP, rilonacept rapidly improved pericarditis signs and symptoms which was associated with HRQoL improvements. For CSD-RP, rilonacept supported tapering/withdrawal of corticosteroids without recurrence, with maintained/improved HRQoL. These results suggest rilonacept can improve RP patient HRQoL while providing an alternative to corticosteroids.
Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2)
Al‐Naamani, Nadine , Krowka, Michael J. , Forde, Kimberly A. , Feng, Rui , Dweik, Raed A. , Bartolome, Sonja, Bull, Todd , Patel, Mamta, Oh, Jae K. , Lin, Grace , Doyle, Margaret F. , Denver, Nina, Andrew, Ruth , Fallon, Michael B. , Group, , for the Pulmonary Vascular Complications of Liver Disease Study, Al-Naamani, Nadine , Krok, Karen , Feng, Rui, Heresi, Gustavo A. , Roberts, Kari E. , Austin, Eric , Hemnes, Anna R. , MacLean, Margaret R. , Kawut, Steven M. , Group, , for the Pulmonary Vascular Complications of Liver Disease Study

Mayo Clinic

Hepatology | May 14, 2020 | Volume: 73 | Issue: 2 | Pages: 726-737

10.1002/hep.31314 | PMID 32407592 Get It

Background and Aims Portopulmonary hypertension (POPH) was previously associated with a single‐nucleotide polymorphism (SNP) rs7175922 in aromatase (cytochrome P450 family 19 subfamily A member 1 [CYP19A1]). We sought to determine whether genetic variants and metabolites in the estrogen signaling pathway are associated with POPH. Approach and Results We performed a multicenter case‐control study. POPH patients had mean pulmonary artery pressure >25 mm Hg, pulmonary vascular resistance >240 dyn‐sec/cm−5, and pulmonary artery wedge pressure ≤15 mm Hg without another cause of pulmonary hypertension. Controls had advanced liver disease, right ventricular (RV) systolic pressure <40 mm Hg, and normal RV function by echocardiography. We genotyped three SNPs in CYP19A1 and CYP1B1 using TaqMan and imputed SNPs in estrogen receptor 1 using genome‐wide markers. Estrogen metabolites were measured in blood and urine samples. There were 37 patients with POPH and 290 controls. Mean age was 57 years, and 36% were female. The risk allele A in rs7175922 (CYP19A1) was significantly associated with higher levels of estradiol (P = 0.02) and an increased risk of POPH (odds ratio [OR], 2.36; 95% confidence interval [CI], 1.12‐4.91; P = 0.02) whereas other SNPs were not. Lower urinary 2‐hydroxyestrogen/16‐α‐hydroxyestrone (OR per 1‐ln decrease = 2.04; 95% CI, 1.16‐3.57; P = 0.01), lower plasma levels of dehydroepiandrosterone‐sulfate (OR per 1‐ln decrease = 2.38; 95% CI, 1.56‐3.85; P < 0.001), and higher plasma levels of 16‐α‐hydroxyestradiol (OR per 1‐ln increase = 2.16; 95% CI, 1.61‐2.98; P < 0.001) were associated with POPH. Conclusions Genetic variation in aromatase and changes in estrogen metabolites were associated with POPH.